|
|
|
201-500 employees
View all
|
|
research
|
|
Utrecht, Utrecht, NL
|
|
Merus is developing best-in-class therapeutics to treat and potentially cure cancer patients. Our most advanced development programs use the Biclonics® format. Biclonics® are capable of simultaneously attacking tumors in multiple ways. For example by activating the immune system to kill tumor cells and directly inhibiting tumor cell growth and survival pathways.
Working at Merus offers opportunity to grow and develop a career that offers both individual and company success. You have the chance to make an impact within the oncology field by being part of the development of bispecific antibody therapies (Biclonics®) to help fight cancer. Merus’ Head Quarters are located in The Netherlands, with offices in the US and collaborators around the world. As of 2016 we are listed on NASDAQ and over a period of 10 years we have several candidate drugs in clinical trials. For more information, please visit www.merus.nl
Read our Community Guidelines: https://merus.nl/community-guidelines/
|
Merus N.V. Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}.{last} | [email protected] |
85.71%
|
The widely used Merus N.V. email format is {f}.{last} (e.g. [email protected]) with 85.71% adoption across the company.
To contact Merus N.V. customer service number in your country click here to find.
Bill Lundberg is the CEO of Merus N.V.. To contact Bill Lundberg email at [email protected]. Or you may call +1.6173199180 or 17869428273
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.